German      French      Chinese

About Endospan

Endospan is a medical device startup in the field of minimally invasive treatment of abdominal, juxta/para-renal and aortic arch aneurysms – AAA JR/PRAA, TAA, Aortic Arch and Ascending Aorta lesions. Endospan’s mission is to transform the treatment of aneurysms, dissections and aortic lesions from high-risk open - surgery to faster, simpler and less invasive procedures. Thus making it the solution of choice for treating patients who otherwise would have limited treatment options. Endospan possesses comprehensive in-house manufacturing & testing facilities and is ISO 13485:2012 accredited by DEKRA. 

Our strategic goal is to provide highly differentiated aortic endografts, to address major underserved clinical needs and patients' subgroups.


  • October 21st, 2015 | Haisco Pharmaceutical Group invests $10M in Endospan

    Chinese second largest medical corporation, Xizang Haisco Pharmaceutical Group Co., Ltd, invests $10M as part of an additional funding round to Endospan.

    Read More »
  • January 26 - January 28, 2016 | Endospan at LINC

    Endospan's team will attend the LINC, between January 26 - January 28, 2016, in Leipzig, Germany.

    Read More »
  • Endospan attended LINC Leipzig, Germany 26-28/1/16

    Read More »
  • Endospan attended The Houston Aortic Symposium, Houston Texas 3-5/3/16

    Read More »
  • Endospan attended Veith Symposium, NYC 15-19/11/16

    Read More »
  • Endospan attended ICI, Israel 4-6/12/16

    The premier international conference for innovations in cardiovascular system (Heart Brain and Peripheral Vessels) and high-tech science industry.

    Read More »
  • Endospan attended LINC Leipzig, Germany 23-26/1/17

    During the conference, Endospan’s team demonstrated the product to doctors and distributors.

    Read More »
  • June 18th, 2015 | Nexus™ hands-on training for US Pilot IDE participating sites

    Endospan conducted its 1st US hands-on training session for investigators from the US and Canada, as a preparatory step for the planed Pilot IDE study, which will be applied for, later this year.

    Read More »
  • April 20, 2015 | Horizon(TM) CE Pivotal Study Enrollment Completion

    Endospan completed enrolling the 30th patient in the Pivotal EU study of the Horizon™, infra-renal AAA endograft system.

    Read More »
  • Single-Sided AAA Repair


    HORIZON – Unilateral, Ultra Low Profile AAA Repair

    The only single-access AAA endograft. 14Fr delivery system for all aortic diameters.
    • Completed FIM & Pivotal EU Study.
    • CE Mark anticipated in mid-2017

  • Endovascular Repair for the Aortic Arch


    NEXUS – Total Aortic Arch Treatment

    An off-the-shelf endograft treatment of the aortic arch. Nexus allows for a short proximal landing zone while providing great intra-procedural control and potential for long-term migration resistance. 20Fr delivery system.
    • Status: On-going clinical studies in the EU (Italy, Switzerland and Germany).
    • CE Mark anticipated mid-2018.
    • Compassionate/Special-Access cases supported, pending ad-hoc MoH/IRB approval.
    • HUD (Humanitarian Use Device) status reaffirmed by US-FDA and IDE submission planned H2 2017